{"id":45584,"date":"2022-06-28T14:01:46","date_gmt":"2022-06-28T12:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/"},"modified":"2022-06-28T14:01:46","modified_gmt":"2022-06-28T12:01:46","slug":"endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/","title":{"rendered":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent"},"content":{"rendered":"
\n

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA<\/a> #NAFLD<\/a>—ENDRA Life Sciences Inc.<\/a> (NASDAQ: NDRA)<\/b>, a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae<\/sup>), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the \u2018272 patent) titled \u201cBroadband Applicator for Thermoacoustic Signal Generation.\u201d\n<\/p>\n

\nThe \u2018272 patent protects TAEUS\u2019 radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad bandwidth, which reduces TAEUS\u2019 sensitivity to tissue variation and temperature. The \u2018272 patent will serve as the parent patent for future patent applications prosecuted in China and Europe.\n<\/p>\n

\n\u201cWe are pleased with the issuance of our 28th<\/sup> patent in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs,\u201d stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon. \u201cWe continue to strengthen our intellectual property (IP) portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 48 patents issued globally.\u201d\n<\/p>\n

\nAbout ENDRA Life Sciences Inc.<\/b>\n<\/p>\n

\nENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae<\/sup>), a ground-breaking technology being developed to visualize tissue like MRI, but at 1\/50th<\/sup> the cost and at the point of patient care. TAEUS\u00ae<\/sup> is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS\u00ae<\/sup> is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS\u00ae<\/sup>, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as \u201capproximate,\u201d “anticipate,” \u201cattempt,\u201d “believe,” “could,” “estimate,” “expect,” \u201cforecast,\u201d \u201cfuture,\u201d “goal,” \u201chope,\u201d “intend,” “may,” “plan,” \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d “seek,” “should,” “will,” \u201cwould,\u201d or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; ENDRA\u2019s ability to find and maintain development partners; market acceptance of ENDRA\u2019s technology and the amount and nature of competition in its industry; and ENDRA\u2019s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA\u2019s business plans; the ability to find and maintain development partners; market acceptance of ENDRA\u2019s technology and the amount and nature of competition in its industry; ENDRA\u2019s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company\u2019s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIrina Pestrikova
\n
Senior Director, Finance
\n
investors@endrainc.com<\/a>
www.endrainc.com<\/a><\/p>\n

Investor Relations:
\n
Yvonne Briggs
\n
LHA Investor Relations
\n
(310) 691-7100
\n
YBriggs@lhai.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NAFLD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the \u2018272 patent) titled \u201cBroadband Applicator for Thermoacoustic Signal Generation.\u201d The \u2018272 patent protects TAEUS\u2019 radiofrequency (RF) applicator … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45584","6":"format-standard","7":"category-industry"},"yoast_head":"\nENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NAFLD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the \u2018272 patent) titled \u201cBroadband Applicator for Thermoacoustic Signal Generation.\u201d The \u2018272 patent protects TAEUS\u2019 radiofrequency (RF) applicator ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T12:01:46+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent\",\"datePublished\":\"2022-06-28T12:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/\"},\"wordCount\":765,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/\",\"name\":\"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-06-28T12:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/","og_locale":"en_US","og_type":"article","og_title":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend","og_description":"ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NAFLD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the \u2018272 patent) titled \u201cBroadband Applicator for Thermoacoustic Signal Generation.\u201d The \u2018272 patent protects TAEUS\u2019 radiofrequency (RF) applicator ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-28T12:01:46+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent","datePublished":"2022-06-28T12:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/"},"wordCount":765,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/","url":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/","name":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-06-28T12:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-enhances-taeus-system-intellectual-property-portfolio-with-issuance-of-28th-u-s-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ENDRA Life Sciences Enhances TAEUS\u00ae System Intellectual Property Portfolio with Issuance of 28th U.S. Patent"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45584"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45584\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}